

1 **Appendix A: Guideline Development** 2 **Groups & Declarations of Interest**

3 **A.1 Guideline development group members**

4

5 **A.1.1 Guideline development group for 2015**

6 **Damien Longson (Guideline Chair)**

7 Consultant Liaison Psychiatrist, Manchester Mental Health and Social Care Trust

8 **Amanda Adler**

9 Consultant Diabetologist, Addenbrooke's Hospital, Cambridge University Hospitals NHS
10 Foundation Trust

11 **Anne Bentley**

12 Medicines Optimisation Lead Pharmacist, NHS East Lancashire Primary Care Trust

13 **Christine Bundy (co-opted expert member)**

14 Senior Lecturer in Behavioural Medicine, Institute for Inflammation & Repair, University of
15 Manchester

16 **Bernard Clarke (co-opted expert member)**

17 Honorary Clinical Professor of Cardiology, Manchester Academic Health Science Centre,
18 University of Manchester

19 **Maria Cowell**

20 Community Diabetes Specialist Nurse, Cambridge

21 **Indranil Dasgupta (co-opted expert member)**

22 Consultant Nephrologist, Birmingham Heartlands Hospital, Heart of England NHS
23 Foundation Trust

24 **David Ronald Edwards**

25 Principal in General Practice, Whitehouse Surgery, Oxfordshire

26 **Andrew Farmer**

27 Professor in General Practice, Department of Primary Care Health Sciences, University of
28 Oxford

1 **Ian Lewin**

2 Consultant Diabetologist, North Devon District Hospital, Northern Devon Healthcare NHS
3 Trust

4 **Natasha Jacques**

5 Principal Pharmacist in Diabetes, Heart of England NHS Foundation Trust, Birmingham

6 **Yvonne Johns**

7 Patient/carer member

8 **Natasha Marsland**

9 Patient/carer member, Diabetes UK

10 **Prunella Neale**

11 Practice Nurse, Herschel Medical Centre, Berkshire

12 **Jonathan Roddick**

13 Principal General Practitioner, Woodseats Medical Centre, Sheffield

14 **Mohammed Roshan (August 2012 - October 2013)**

15 Principal in General Practice, Leicester City and County

16 **Sailesh Sankar**

17 Consultant Diabetologist, University Hospitals Coventry and Warwickshire NHS Trust

A.182 Guideline development group for 2009 (NICE clinical guideline 87)

19 **Amanda Adler (Chair)**

20 Consultant Physician with an interest in diabetes, Addenbrooke's Hospital, Cambridge

21 **Claudette Allerdycce**

22 Principal Locality Pharmacist, Croydon Primary Care Trust

23 **Tony Doherty**

24 Diabetes Nurse Specialist and Service Improvement Officer, Diabetes UK (Scotland)

25 **Andrew Farmer**

26 University Lecturer in General Practice, University of Oxford

27 **Niru Goenka**

28 Consultant Physician with an interest in diabetes/endocrinology, Countess of Chester NHS
29 Foundation Trust

1 **Martin Hadley-Brown**

2 General Practitioner, Thetford, Norfolk; Clinical Teacher at University of Cambridge Clinical
3 School of Medicine

4 **Philip Home**

5 Professor of Diabetes Medicine and Consultant Physician in Diabetes and Metabolic
6 Medicine, Newcastle Primary Care Trust

7 **Philip Ivory**

8 Patient/carer representative

9 **Yvonne Johns**

10 Patient/carer representative

11 **Ian Lewin**

12 Consultant Physician with an interest in diabetes/endocrinology, North Devon District
13 Hospital

14 **Alistair McGuire**

15 Head of Social Policy, London School of Economics

16 **Julie Wood**

17 Diabetes Nurse Specialist, Diabetes and Renal Programme Manager, Kirklees Primary Care
18 Trust

19 The following people were not full members of the GDG but were co-opted onto the group as
20 expert advisers:

21 **Anthony Barnett**

22 Professor of Medicine, University of Birmingham and Heart of England NHS Foundation
23 Trust

24 **Andrew Krentz**

25 Consultant in Diabetes and Endocrinology, Southampton University Hospitals

26 The following individual contributed expertise:

27 **Alistair Gray**

28 Director of the Health Economics Research Centre, Division of Public Health and Primary
29 Care, University of Oxford

30 The Short Clinical Guidelines Technical Team was responsible for this guideline throughout
31 its development. It was responsible for preparing information for the GDG, for drafting the
32 guideline and for responding to consultation comments. The following people, who are
33 employees of NICE, made up the technical team working on this guideline.

1 **Tim Stokes**

2 Associate Director

3 **Beth Shaw**

4 Technical Adviser

5 **Francis Ruiz**

6 Technical Adviser in Health Economics

7 **Michael Heath**

8 Project Manager

9 **Lynda Ayiku**

10 Information Specialist

A.1.3 Guideline development group for 2008 (NICE clinical guideline 66)

12 **Professor Jonathan Mant (Chair)**

13 Professor of Primary Care Stroke Research, University of Birmingham

14 **Mrs Lina Bakhshi**

15 Information Scientist, NCC-CC

16 **Mrs Margaret Bannister**

17 Nurse Consultant in Diabetes Care, Bradford and Airedale Primary Care Trust

18 **Mrs Katherine Cullen**

19 Health Economist, NCC-CC

20 **Professor Melanie Davies**

21 Professor of Diabetes Medicine, University of Leicester

22 **Dr Jose Diaz**

23 Health Services Research Fellow in Guideline Development, NCC-CC

24 **Mrs Barbara Elster**

25 Patient and Carer Representative, Essex

26 **Dr Roger Gadsby**

27 General Practitioner and Senior Lecturer in Primary Care, Warwickshire

28 **Dr Anupam Garrib**

29 Health Services Research Fellow, NCC-CC

- 1 **Ms Irene Gummerson**
- 2 Primary Care Pharmacist, Yorkshire
- 3 **Dr Martin Hadley-Brown**
- 4 General Practitioner Trainer, University of Cambridge
- 5 **Professor Philip Home**
- 6 Clinical Advisor to the GDG; Professor of Diabetes Medicine, Newcastle University
- 7 **Mrs Kathryn Leivesley**
- 8 Practice Nurse, North Manchester Primary Care Trust
- 9 **Mrs Emma Marcus**
- 10 Clinical Specialist Diabetes Dietitian, Hinckley and Bosworth Primary Care Trust
- 11 **Mr Leo Nherera**
- 12 Health Economist, National Collaborating Centre for Women's and Children's Health
- 13 **Ms Roberta Richey**
- 14 Health Services Research Fellow in Guideline Development, NCC-CC
- 15 **Mr John Roberts**
- 16 Patient and Carer Representative, Merseyside
- 17 **Dr Mark Savage**
- 18 Consultant Physician, North Manchester General Hospital
- 19 **Lorraine Shaw**
- 20 Paediatric Diabetes Clinical Nurse Specialist, Birmingham Children's Hospital
- 21 **Dr Stuart Smelie**
- 22 Consultant Chemical Pathologist, Bishop Auckland General Hospital
- 23 **Ms Nicole Stack**
- 24 Guideline Development Project Manager, NCC-CC
- 25 **Ms Claire Turner**
- 26 Guideline Development Senior Project Manager, NCC-CC
- 27 **Ms Susan Varney**
- 28 Health Services Research Fellow in Guideline Development, NCC-CC

1 **Dr Jiten Vora**

2 Consultant Physician Endocrinologist, Royal Liverpool and Broadgreen University Hospital

3 The following experts were invited to attend specific meetings and to advise the Guideline
4 Development Group:

5 **Dr Julian Barth**

6 Consultant Chemical Pathologist, Leeds NHS Trust attended one meeting as a deputy for Dr
7 Stuart Smellie

8 **Dr Indranil Dasgupta**

9 Consultant Physician and Nephrologist, Birmingham Heartlands Hospital

10 **Dr Michael Feher**

11 Consultant Physician, Chelsea Westminster Hospital attended one meeting as a deputy for
12 Dr Mark Savage

13 **Dr Charles Fox**

14 Consultant Physician, Northampton General Trust attended one meeting as a deputy for
15 Professor Melanie Davies

16 **Natasha Jacques**

17 Principal Pharmacist Medicine, Solihull Hospital attended one meeting as a deputy for Ms
18 Irene Gummerson

19 **Dr Eric Kilpatrick**

20 Consultant Chemical Pathologist, University of Hull attended one meeting as a deputy for Dr
21 Stuart Smellie

22 **Dr Ian Lawrence**

23 Consultant Diabetologist, University of Leicester attended one meeting as a deputy for
24 Professor Melanie Davies and Dr Jiten Vora

25 **Professor Sally Marshall**

26 Professor of Diabetes, Newcastle University

27 **Professor David Wood**

28 Professor of Cardiovascular Medicine, Imperial College London

29 **CG66 Acknowledgements**

30 The Guideline Development Group (GDG) is grateful to Bernard Higgins, Jane Ingham, Rob
31 Grant, Jill Parnham and Susan Tann of the NCC-CC for their support throughout the
32 development of the guideline.

- 1 The GDG would like to thank the following individuals for giving their time to advise us
2 regarding the design and interpretation of the economic model of analysis of third-line
3 therapy with insulins, glitazones or exenatide in Type 2 diabetes:
- 4 • Professor Alastair Gray, University of Oxford
 - 5 • Dr Philip Clarke, University of Sydney
 - 6 • Dr Joanne Lord, National Institute for Health and Clinical Excellence.
- 7 The GDG would like to thank the following individuals for peer reviewing the guideline:
- 8 • Professor Simon Heller, University of Sheffield
 - 9 • Professor David Owens, Llandough Hospital, Penarth
 - 10 • Professor Bryan Williams, University of Leicester
 - 11 • Dr Miles Fisher, Glasgow Royal Infirmary
 - 12 • Professor Solomon Tesfaye, University of Sheffield
 - 13 • Mr Irvine Turner, Patient Representative.
- 14
15

A.2 Declarations of interests

A.2.1 Declarations of interest for 2015

3

GDG Member	Interest Declared	Declared when?	Type of Interest	Decisions Taken
Amanda Adler - Diabetologist	None declared	July 2012	N/A	N/A
Christine Bundy (co-opted expert in mental health)	Holds a Scientific Advisory Board position with Simple Healthcare Products for which an honorarium is received for attending approximately three meetings per year.	July 2012	Non-specific personal pecuniary interest	Declare and participate
Maria Cowell – Community Diabetes Nurse Specialist	None declared	August 2012	N/A	N/A
Indranil Dasgupta (co-opted expert nephrologist)	Has been a member of an advisory board on a new phosphate binder for chronic kidney disease for Mitsubishi Pharma Indranil Dasgupta (co-opted expert nephrologist)	June 2013	Non-specific personal pecuniary interest	Declare and participate
Indranil Dasgupta (co-opted expert nephrologist)	Indranil Dasgupta (co-opted expert nephrologist)	June 2013	Non-specific, non-personal pecuniary interest	Declare and participate
David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)	Acts as a Chair and member on a number of advisory boards. Has organised, chaired and presented at local, national and international meetings on male and/ or female sexual problems and stress. Has written guidelines, been filmed, reviewed/ written articles for both lay and medical press. These activities have been reimbursed by organisations including pharmaceutical companies in the form of transport, accommodation and	July 2013	Non-specific personal pecuniary interest	Declare and participate

	<p>sometimes honoraria. Companies that travel, accommodation and honoraria have been received from are Bayer, Eli Lilly, Schwabe and Takeda & Menarini, Pfizer, ProStrakan and Owen Mumford.</p>			
<p>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</p>	<p>President of the British Society for Sexual Medicine, Member of Men's Health Expert Policy Group which aims to educate those in power especially Government and key stake holders. Travel/occasional accommodation but not time is paid for by Bayer.</p>	<p>July 2013</p>	<p>Non-specific personal pecuniary interest</p>	<p>Declare and participate</p>

<p>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</p>	<p>Clinical advisor to the Klinefelter's National Association. Member of an advisory board for prostate cancer management known as atypical small acinar proliferation (ASAP).</p>	<p>July 2013</p>	<p>Non-specific personal pecuniary interest</p>	<p>Declare and participate</p>
<p>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</p>	<p>Participated as a medical researcher for studies undertaken by the Universities of Oxford and Southampton.</p>	<p>July 2013</p>	<p>Non-specific personal pecuniary interest</p>	<p>Declare and participate</p>
<p>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</p>	<p>Chief investigator in the UK for a study on low dose aspirin. The study is sponsored by Bayer.</p>	<p>July 2013</p>	<p>Non-specific personal pecuniary interest</p>	<p>Declare and participate</p>

Andrew Farmer – GP with a special interest in diabetes (joined the GDG on 7/11/2013) -	None declared	November 2013	N/A	N/A
Anne Bentley – Primary Care Pharmacist	None declared	July 2012	N/A	N/A
Natasha Jacques – Secondary Care Pharmacist	Participation in advisory board on Management of Diabetes in Renal Disease (sponsored by Boehringer Ingelheim) 17.01.12	August 2012	Specific personal pecuniary interest	Declare and participate as in line with NICE policy, it is greater than one year since the conflict occurred and the topics this may relate to are discussed
Natasha Jacques – Secondary Care Pharmacist	Speaker on ‘Adherence Issues in Diabetes’- event sponsored by MSD 25.04.12	August 2012	Specific personal pecuniary interest	Declare and participate as in line with NICE policy, it is greater than one year since the conflict occurred and the topics this may relate to are discussed
Yvonne Johns – patient/carer member	Has been asked by Diabetes UK Wales on behalf of the Welsh Medical Council to discuss and bring forward patient views on lixisenatide for the diabetes group in which she is involved. None of the patients have been asked to use the	Sept 2013	Personal non-pecuniary interest	Declare and participate

	drug but were asked whether they would consider using it based in an information leaflet they received and their experiences of other GLP1's			
Ian Lewin - Diabetologist	None declared	April 2012	N/A	N/A
Natasha Marsland – patient/carer member	Employed by Diabetes UK	Oct 2012	Non-personal pecuniary interest	Declare and participate
Prunella Neale – Practice nurse	None declared	Oct 2012	N/A	N/A
Jonathan Roddick - GP	Member of MSD advisory board for sitagliptin until appointment.	April 2012	Specific personal pecuniary interest(s)	Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.
Mohamed Roshan – GP (August 2012 – October 2013)	Attended a diabetes advisory meeting. Reimbursement paid to the GP practice.	April 2012	Specific non-personal pecuniary interest	Declare and participate
Mohamed Roshan – GP (August 2012 – October 2013)	Developer of Diabetes Education modules in Leicester which include modules on diabetes therapies between 2011 and 2013. No money was received.	October 2013	Personal non-pecuniary interest	Declare and participate
Mohamed Roshan – GP (August 2012 – October 2013)	Developed and chaired meetings for GLP-1 educational program in Leicester for Primary Care as part of Department of Diabetes	October 2013	Personal non-pecuniary interest	Declare and participate
Mohamed	Attends advisory committee on	October	Specific	Declare and withdraw

Roshan – GP (August 2012 – October 2013)	Lixisenatide for Sanofi and will be trained in future as speaker (last attended March 2013). Received reimbursement to cover locum fees and staff time.	2013	personal pecuniary interest	
Mohamed Roshan – GP (August 2012 – October 2013)	Will attend conference for discussion on saxagliptin and cardiovascular outcomes evidence recently published. Reimbursement from Astra Zeneca	October 2013	Specific personal pecuniary interest	Declare and withdraw
Mohamed Roshan – GP (August 2012 – October 2013)	Will be training as speaker for Bristol Myer Squibb	October 2013	Specific personal pecuniary interest	Declare and withdraw
Mohamed Roshan – GP (August 2012 – October 2013)	Have chaired meeting for Insulin Degludec (Tresiba) in Sept 2013. Locum expenses reimbursed by Novo Nordisk.	October 2013	Specific personal pecuniary interest	Declare and withdraw
Sailesh Sankar - Diabetologist	Attended the International Diabetes Federation in 4th December 2011, the travel and subsistence was supported by Boehringer Ingleheim with in the ABPI regulation guidelines.	July 2012	Specific personal pecuniary interest(s)	Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.

Sailesh Sankar - Diabetologist	Chaired an evening meeting on the 12th of June 2012 for GP educational session supported by Novo nordisk.	July 2012	Specific personal pecuniary interest(s)	Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.
Sailesh Sankar - Diabetologist	October 2011 - did an evening educational session for GP's supported by Boehringer Ingleheim.	July 2012	Specific personal pecuniary interest(s)	Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.
Sailesh Sankar - Diabetologist	Principal Investigator for Roche EXPERT study. The study recruited patient to use an EXPERT bolus advisor blood glucose monitor versus a Nano monitor. This study was in relation to feasibility of use of bolus advisor in patients with Type 1 diabetes. In this study 9 patients were recruited from Feb 2012 onwards and study was completed in October 2012. This study was funded by	October 2012	Non-personal specific pecuniary interest(s)	Declare and participate

	ROCHE to meet the expenses of the overheads and running of the study at UHCW site. The UHCW Trust has invoiced the company and the funding yet to be received. The exact amount can be confirmed on receipt.			
Sailesh Sankar - Diabetologist	Research nurse team was also involved in a retrospective data collection for study/audit conducted at UHCW trust in relation to use of INSULINX blood glucose monitoring in patients with Type 1 diabetes. Funding was (£150.00 per patient data collected) was agreed by the trust R and D in relation to this project. This study was funded by ABOTT diabetes care This was done over September to October 2012 period. Approximately 10 patient's data was collected for this study.	July 2013	Specific non-personal pecuniary interest	Declare and participate
Sailesh Sankar - Diabetologist	Receiving a grant from Novo Nordisk to lead development of an education application for computer and phone devices for clinicians and medical students. The application will covering managing blood glucose levels for people with diabetes on insulin and preventing ketoacidosis. Novo Nordisk produce insulin licensed for us in people with type 1 and type 2 diabetes.	July 2013	Specific non-personal pecuniary interest	Declare and participate

1

A.22 Declarations of interest for 2009 (NICE clinical guideline 87)

3

4

Name	Interest declared	Declared when?	Type of interest?	Decisions taken
Amanda Adler (Chair)	None	February 2008	N/A	N/A
Philip Home	Lecturing and consultation contracted by Newcastle University: • Novo Nordisk: pre-mix insulin analogues; insulin detemir research	February 2008	Non- personal pecuniary interest	Declare and participate

Name	Interest declared	Declared when?	Type of interest?	Decisions taken
	<ul style="list-style-type: none"> • Sanofi-aventis: insulin glargine consultation; rimonabant consultation • Roche diagnostics: Accu-check self-monitoring equipment lecturing and consultation • Merck MSD: sitagliptin lecturing and consultation Merck Serono: metformin consultation • Novartis: vildagliptin consultation • GlaxoSmithKline: rosiglitazone research; also pipeline products not in the update - consultation • Groupe Servier: gliclazide research and consultation; pipeline products • Eli Lilly: support to International Diabetes Federation only - not product specific (they manufacture insulins and exenatide) • Takeda: pioglitazone - support to International Diabetes Federation; also writing support for review I note that all the above have supported the International Diabetes Federation on various initiatives (eg evidence-based guidelines) on which I have been lead; I will be expected to support the next World Diabetes Congress for which I am Programme Committee Chair. 	February 2008	Non- personal pecuniary interest	Declare and participate
Niru Goenka	<p>Research grant awarded by Sanofi-Aventis in January 2007 of £4500 to the department for studying the prevalence of untreated cardiovascular risk factors in a diabetic retinopathy laser clinic.</p> <p>15/5/2007 "Insulin Glulisine (Apidra) Advisory Board Meeting – attended Sanofi advisory board.</p> <p>21/06/08 "Update on local glycaemic guidelines" – speaker at MSD sponsored meeting</p> <p>05/09/08 "How to get a consultant's post" – speaker for local SpR teaching programme with sponsorship provided by Sanofi-Aventis.</p> <p>06/09/08 "Management of Dyslipidaemia" – speaker at Shering Plough sponsored meeting.</p> <p>17/9/07 – 21/9/07 "EASD 2007 in Amsterdam" – I received a travel grant from Takeda to attend this</p>	February 2008	Non-personal pecuniary interest	Declare and participate

Name	Interest declared	Declared when?	Type of interest?	Decisions taken
	<p>meeting. The grant paid for economy class flights, accommodation and registration for the meeting. I was not required (and did not) attend any Takeda symposium or meeting at this venue and received no personal payment (flights, accommodation and meeting registration were arranged by Takeda within ABPI guidelines – I did not actually receive any money).</p> <p>15/11/08 “Novel approaches to hypertension” – I chaired a session at a meeting sponsored by Novartis.</p> <p>20/11/08 “eGFR and Diabetes in General Practice” – speaker at Shering Plough sponsored meeting.</p> <p>27/11/08 “Changes in the NHS and how they will affect diabetes care” – speaker at Eli Lilly sponsored meeting.</p> <p>15/01/08 “Current controversies in Diabetes Care” – speaker at MSD sponsored meeting</p> <p>24/1/08 “Preparing for the future – how to get a consultants post” – speaker at Manchester Respiratory SpR teaching (event was sponsored by GSK).</p> <p>11/3/08 “Aliskiren – Regional Advisory Board meeting” – attended Novartis Advisory Board.</p> <p>13/5/08 “Medicolegal aspects in Diabetes Care” – speaker at Takeda sponsored meeting.</p> <p>09/7/08 Debate “Should diabetes be managed exclusively in primary care” – speaker at Takeda sponsored meeting.</p> <p>23/7/08 “How not to get sued in Diabetes Care” – speaker at MSD sponsored meeting.</p> <p>12/08/08 “Update on local diabetic glycaemic guidelines” – speaker at Eli Lilly sponsored meeting.</p> <p>07/10/08 “New developments in Diabetes” – speaker at Eli Lilly sponsored meeting.</p> <p>06/11/08 “Individualising treatment in Diabetes” – speaker at Novartis sponsored meeting</p> <p>04/02/09 “GSK Round Table discussion on potential results of RECORD study” – attended GSK regional advisory board meeting</p>			

Name	Interest declared	Declared when?	Type of interest?	Decisions taken
	<p>My department has previously received research grants from GSK (more than 12 months ago) and Sanofi-Aventis (within the last 12 months).</p> <p>Our department is receiving support from Eli Lilly for development of our diabetes website – this involves permission to use the basic IT structure and design of the website & the provision of project management training to the project team. No payments are being made to any member of our team as part of this project.</p> <p>I have given lectures and chaired meetings sponsored by MSD, Eli Lilly, Schering-Plough, Sanofi-Aventis and Novartis. These have been non-promotional and non-product related. In addition any honoraria from these meetings are paid to our departmental diabetes education and research trust fund, or other registered charities. Our department is currently carrying out a research study sponsored by Sanofi-Aventis. Any payment from this will be to departmental funds.</p> <p>12/08/08 “Update on local diabetic glycaemic guidelines” – speaker at Eli Lilly sponsored meeting. I am a committee member of ABCD</p>	<p>February 2008</p> <p>February 2008</p>	<p>Non-personal pecuniary interest</p> <p>Personal non-pecuniary interest</p>	<p>Declare and participate</p> <p>Declare and participate</p>
Ian Lewin	None	February 2008	N/A	N/A
Andrew Farmer	<p>Oxford University received a fee for my delivering a postgraduate educational seminar at a non-promotional meeting organised by MSD on 18th July 2007. I spoke on the role of Diabetes Research Networks in the NHS for ensuring delivery of research evidence to inform clinical practice. I was a member of an advisory board to review data on inhaled insulin convened by Novo in November 2007, fees were paid to Oxford University.</p> <p>Some payments have been received by the Oxford Radcliffe Hospital from a trial that was completed. These payments were from Eli Lilly and Company.</p>	February 2008	Non-personal pecuniary	Declare and participate

Name	Interest declared	Declared when?	Type of interest?	Decisions taken
Martin Hadley-Brown	<p>Served on advisory boards relating to agents or equipment used in diabetes management for the following companies: Novo Nordisk, Glaxo Smith Kline, Takeda, Roche, Sanofi Aventis, Merck Sharp & Dohme, Pfizer.</p> <p>Spoken at educational meetings sponsored by some or all of the above companies.</p> <p>Advisory meetings 20/07/8 19/4/07 Takeda 27/6/07 Novo Nordisk (International Liaison meeting following American Diabetes Assn meeting) 6/7/07 Glaxo SmithKline 20/7/07 Novartis 'Round Table' clinicians discussion. 9/8/07 Astra Zeneca 19/10/07 Merck Sharp & Dohme. 8/11/07 Glaxo SmithKline 30/1/08 Roche Pharmaceuticals 2/4/08 Sanofi Aventis. As a committee member of the Primary Care Diabetes Society, the Society has received sponsorship in the form of unrestricted educational grants from a variety of the pharmaceutical companies named above</p>	February 2008	Non-personal pecuniary	Declare and participate
Tony Doherty	Presently working on a 2 year secondment with Diabetes UK as Service Advisor from my present Community Nurse Specialist post. Secondment commenced 15.01.08.	March 2008	Personal non-pecuniary interest	Declare and participate
Julie Wood	None	March 2008	N/A	N/A
Claudette Allerdyce	None	February 2008	N/A	N/A
Yvonne Johns	None	February 2008	N/A	N/A
Philip Ivory	None	March 2008	N/A	N/A
Alistair McGuire	Advisory work for GSK but money received by working department	March 2008	Non-personal pecuniary interest	Declare and participate
Tony Barnett	Regularly advise Industry on new product development for diabetes including remuneration for such advice on Advisory Boards. Received remuneration for lectures at scientific meetings supported by Industry. Specifically, this includes companies involved in developing new products for diabetes including	February 2008	Personal pecuniary interest	Decision to appoint as a co-opted expert only due to personal pecuniary interests declared.

Name	Interest declared	Declared when?	Type of interest?	Decisions taken
	<p>GlaxoSmithKline, Takeda, Eli Lilly, Novartis, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Astra Zeneca and Bristol Myers Squibb.</p> <p>I have received competitive grants for research from the relevant companies mentioned below: GlaxoSmithKline, Takeda, Eli Lilly, Novartis, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Astra Zeneca and Bristol Myers Squibb.</p>		Non-personal pecuniary interest	
Andrew Krentz	None	February 2008	N/A	N/A

1

A.3 Declarations of interest for 2006 (NICE clinical guideline 66)

3 **Mrs Margaret C Bannister** (Signed 22/06/2007)

4 Personal pecuniary interest:

- 5 • None

6 Personal family interest:

- 7 • Sister employed by Astra Zeneca as sales representative. As a member of their academy
 8 she had a weekend in Seville in June, to whom a partner was invited and I attended in this
 9 capacity.

10 Non-personal pecuniary interest:

- 11 • Any honorariums paid for lectures I deliver are paid directly to my employing PCT in the
 12 last 12 months I have been paid for such lectures by:
 13 ○ Takeda £150
 14 ○ GlaxoSmithKline £150

15 Personal non-pecuniary interest:

- 16 • None

17 **Professor Melanie Davies** (Signed 17/07/2007)

18 Personal pecuniary interest:

- 19 • Advisory Board for Eli Lilly (exenatide)
 20 • Speaker fees for Sanofi-Aventis (insulin glargine)
 21 • Advisory Board for Novo Nordisk (insulin detemir)
 22 • Advisory Board for MSD for DPP IV and ezetimibe

23 Personal family interest:

- 24 • None

25 Non-personal pecuniary interest:

- 26 • Educational research grants from Servier/Pfizer and Novo Nordisk to support
 27 departmental research

- 1 Personal non-pecuniary interest:
- 2 • Principal investigator for the DESMOND RCT
- 3 **Mrs Barbara Elster** (Signed 18/07/2007)
- 4 Personal pecuniary interest:
- 5 • None
- 6 Personal family interest:
- 7 • None
- 8 Non-personal pecuniary interest:
- 9 • None
- 10 Personal non-pecuniary interest:
- 11 • None
- 12
- 13 **Dr Roger Gadsby** (Signed 17/07/2007)
- 14 Personal pecuniary interest:
- 15 • Member of Advisory Board for Novo Nordisk, Takeda, Pfizer, MSD and Merck Pharma.
- 16 • Speaker at educational events sponsored by Merck Pharma
- 17 Personal family interest:
- 18 • None
- 19 Non-personal pecuniary interest:
- 20 • I am Medical Advisor to Warwick Diabetes Care at Warwick Medical School, Warwick
- 21 University, an organisation which provides diabetes educational programmes across the
- 22 UK. Several of the courses are supported by unrestricted educational grants from pharma
- 23 companies. In the past 12 months these have been from Novo Nordisk, Eli Lilly, GSK,
- 24 Sanofi-Aventis and Lifescan.
- 25 I am Honorary Treasurer of the Primary Care Diabetes Society which has received
- 26 educational grants from GSK, Takeda, Novo Nordisk, Eli Lilly, Sanofi-Aventis, Servier,
- 27 Roche Diagnostics and Merck Pharma.
- 28 Personal non-pecuniary interest:
- 29 • None
- 30 **Ms Irene Gummerson** (Signed 20/06/07)
- 31 Personal pecuniary interest:
- 32 • None
- 33 Personal family interest:
- 34 • None
- 35 Non-personal pecuniary interest:
- 36 • None
- 37 • Personal non-pecuniary interest:
- 38 • None
- 39 **Dr Martin Hadley-Brown** (Signed 17/07/2007)
- 40 Personal pecuniary interest:
- 41 • Lecture and Advisory Board fees received from GSK, Takeda, Novartis, Novo Nordisk,

- 1 Astra Zeneca. Only one of these (Novo Nordisk) exceeds £1,000 over the calendar year.
- 2 Personal family interest:
- 3 • None
- 4 Non-personal pecuniary interest:
- 5 • None
- 6 Personal non-pecuniary interest:
- 7 • None
- 8 **Professor Philip D Home** (Signed 21/07/2007)
- 9 Personal pecuniary interest:
- 10 • Shareholder (medical industries only): NONE Other earnings (private practice/other/legal
- 11 reports) Total under £1,000 p.a.
- 12 Personal family interest:
- 13 • As a medical writer my wife occasionally has contracts with some of the companies
- 14 named above.
- 15 • She has some funding from IDF and Novo Nordisk projects as above. She has no
- 16 personal interest otherwise in any medical commercial organisation.
- 17 • I have no children under age 18 years.
- 18 Non-personal pecuniary interest:
- 19 • Continuing intermittent consultation (relates to diabetes/lipid technologies only) for
- 20 external commercial healthcare organisations (on behalf of University of Newcastle upon
- 21 Tyne):
- 22 Non-personal:
- 23 • Sanofi-Aventis, Paris/Guildford
- 24 • GlaxoSmithKline plc, Brentford
- 25 • Pfizer Inc, New York NY
- 26 • Merck Inc, Whitehouse Station NJ Merck-
- 27 • Sante, Paris
- 28 • Novo Nordisk A/S, Copenhagen / Crawley
- 29 • Novartis, Basel
- 30 • Recherche Groupe Servier, Paris Roche Diagnostics, Mannheim.
- 31 Other consultation for commercial organisations in last 12 months:
- 32 • UK and US financial, banking, conference, management consultancy, and support
- 33 companies (when not knowingly commissioned by named pharmaceutical/diagnostic
- 34 healthcare companies)
- 35 • Research/project grant support to hospital or university:
- 36 • Novo Nordisk A/S (discussions with Merck MSD UK, Pfizer UK) International Diabetes
- 37 Federation:
- 38 • The IDF receives funding from all the above companies except Novartis but also Eli Lilly
- 39 and Co, Takeda and Merck Sante for activities (Clinical Guidelines Task Force) in which I
- 40 am involved but not remunerated for. If I change responsibilities at IDF this may extend to
- 41 all concerns in the diabetes healthcare area.
- 42 Directorships:
- 43 • North East Diabetes Trust (charity) Diabetes Network International (charity)

- 1 • WorldWIDE Initiative for Diabetes Education (non-profit company)
2 • WorldWIDE is supported by GlaxoSmithKline, Merck Inc, Novartis, Pfizer and Sanofi-
3 Aventis
- 4 Personal non-pecuniary interest:
5 • None
- 6 **Mrs Emma Marcus** (Form signed 25/06/2007)
- 7 Personal pecuniary interest:
8 • None
- 9 Personal family interest:
10 • None
- 11 Non-personal pecuniary interest:
12 • None
- 13 Personal non-pecuniary interest:
14 • None
- 15 **Professor Jonathan Mant** (Form signed 18/07/2007)
- 16 Personal pecuniary interest:
17 Consulting for:
18 • Expert-24 (Norwich Union website)
19 • PharmaSwiss (company that markets drugs in ex-Yugoslavia)
- 20 Personal family interest:
21 • Brother works for Quintiles (Biotech company)
- 22 Non-personal pecuniary interest:
23 • None
- 24 Personal non-pecuniary interest:
25 • Associate Director Schote Research Network
- 26 **Mr John Roberts** (Form signed 18/07/2007)
- 27 Personal pecuniary interest:
28 • None
- 29 Personal family interest:
30 • None
- 31 Non-personal pecuniary interest:
32 • None
- 33 Personal non-pecuniary interest:
34 • None
- 35 **Dr Mark Savage**
- 36 Personal pecuniary interest:
37 • Honoraria received for educational talks to GP/nurses from GSK, Takeda, Lilly, Novartis
38 and Novo-Nordisk

- 1 Personal family interest:
- 2 • None
- 3 Non-personal pecuniary interest:
- 4 • None
- 5 Personal non-pecuniary interest:
- 6 • None
- 7 **Dr Stuart Smellie** (Form signed 18/07/2007)
- 8 Personal pecuniary interest:
- 9 • Occasional lecturing for Merck, Astra-Zeneca and MSD on lipid lowering and advisor in
10 occasional advertising boards
- 11 Personal family interest:
- 12 • None
- 13 Non-personal pecuniary interest:
- 14 • None
- 15 Personal non-pecuniary interest:
- 16 • None
- 17 **Dr Vora Jiten** (Form signed 18/07/2007)
- 18 Personal pecuniary interest:
- 19 • As previously declared:
- 20 • Previous lecturing fees, honoraria for educational meetings from/for: GSK, Takeda,
21 NovoNordisk, Lilly, Sanofi-Aventis, MSD, Novartis
- 22 Personal family interest:
- 23 • None
- 24 Non-personal pecuniary interest:
- 25 • None
- 26 Personal non-pecuniary interest:
- 27 • None
- 28